| Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation SG Holtan, TE DeFor, A Lazaryan, N Bejanyan, M Arora, CG Brunstein, ... Blood, The Journal of the American Society of Hematology 125 (8), 1333-1338, 2015 | 449 | 2015 |
| Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents SG Holtan, DJ Creedon, P Haluska, SN Markovic Mayo Clinic Proceedings 84 (11), 985-1000, 2009 | 353 | 2009 |
| A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality ML MacMillan, M Robin, AC Harris, TE DeFor, PJ Martin, A Alousi, VT Ho, ... Biology of Blood and Marrow Transplantation 21 (4), 761-767, 2015 | 276 | 2015 |
| Acute graft-versus-host disease: a bench-to-bedside update SG Holtan, M Pasquini, DJ Weisdorf Blood, The Journal of the American Society of Hematology 124 (3), 363-373, 2014 | 264 | 2014 |
| Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc … J Bolaños-Meade, R Reshef, R Fraser, M Fei, S Abhyankar, Z Al-Kadhimi, ... The Lancet Haematology 6 (3), e132-e143, 2019 | 230 | 2019 |
| Diagnosis of obesity by primary care physicians and impact on obesity management A Bardia, SG Holtan, JM Slezak, WG Thompson Mayo Clinic Proceedings 82 (8), 927-932, 2007 | 212 | 2007 |
| Immunomodulation in COVID-19 NE Ingraham, S Lotfi-Emran, BK Thielen, K Techar, RS Morris, SG Holtan, ... The Lancet Respiratory Medicine 8 (6), 544-546, 2020 | 196 | 2020 |
| Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanoma RD Rao, SG Holtan, JN Ingle, GA Croghan, LA Kottschade, ET Creagan, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 172 | 2006 |
| Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors K Margolin, C Morishima, V Velcheti, JS Miller, SM Lee, AW Silk, ... Clinical Cancer Research 24 (22), 5552-5561, 2018 | 170 | 2018 |
| Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition EI Buchbinder, JP Dutcher, GA Daniels, BD Curti, SP Patel, SG Holtan, ... Journal for immunotherapy of cancer 7, 1-7, 2019 | 153 | 2019 |
| Fetal sex‐based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period EAL Enninga, WK Nevala, DJ Creedon, SN Markovic, SG Holtan American journal of reproductive immunology 73 (3), 251-262, 2015 | 146 | 2015 |
| WHO-defined ‘myelodysplastic syndrome with isolated del (5q)’in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations MM Patnaik, TL Lasho, CM Finke, N Gangat, D Caramazza, SG Holtan, ... Leukemia 24 (7), 1283-1289, 2010 | 116 | 2010 |
| Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors A Lazaryan, DJ Weisdorf, T DeFor, CG Brunstein, ML MacMillan, ... Biology of Blood and Marrow Transplantation 22 (1), 134-140, 2016 | 95 | 2016 |
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and … CL Kitko, J Pidala, HM Schoemans, A Lawitschka, ME Flowers, ... Transplantation and cellular therapy 27 (7), 545-557, 2021 | 90 | 2021 |
| Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis J Bolaños-Meade, M Hamadani, J Wu, MM Al Malki, MJ Martens, ... New England Journal of Medicine 388 (25), 2338-2348, 2023 | 89 | 2023 |
| Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells A Kariminia, SG Holtan, S Ivison, J Rozmus, MJ Hebert, PJ Martin, SJ Lee, ... Blood, The Journal of the American Society of Hematology 127 (24), 3082-3091, 2016 | 88 | 2016 |
| Perspectives of cancer patients and their health during the COVID-19 pandemic E Lou, D Teoh, K Brown, A Blaes, SG Holtan, P Jewett, H Parsons, ... PloS one 15 (10), e0241741, 2020 | 83 | 2020 |
| Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis AS Mansfield, SG Holtan, TE Grotz, JB Allred, JW Jakub, LA Erickson, ... Modern Pathology 24 (4), 487-494, 2011 | 75 | 2011 |
| Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma EAL Enninga, SG Holtan, DJ Creedon, RS Dronca, WK Nevala, ... Mayo clinic proceedings 89 (4), 520-535, 2014 | 74 | 2014 |
| Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma EAL Enninga, WK Nevala, SG Holtan, AA Leontovich, SN Markovic Melanoma research 26 (5), 429-441, 2016 | 70 | 2016 |
